AI assistant
FEEDBACK PLC — Regulatory Filings 2020
Jan 21, 2020
7636_rns_2020-01-21_20725509-5eb6-456a-a102-a1bfe7c33547.html
Regulatory Filings
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 3870A
Feedback PLC
21 January 2020
Feedback plc
Change of Registered Office
London, 21 January 2020: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, announces that its registered office has changed to Health Foundry, Canterbury House, 1 Royal St, London SE1 7LL, with immediate effect.
-Ends-
Enquiries:
| Feedback plc Tom Oakley, CEO Lindsay Melvin, CFO |
+44 (0)1954 718072 [email protected] |
| Allenby Capital Limited (Nominated Adviser) David Worlidge / Asha Chotai |
+44 (0)20 3328 5656 |
| Peterhouse Capital Limited (Joint Broker) Lucy Williams / Duncan Vasey |
+44 (0)20 7469 0936 |
| Stanford Capital Partners Limited (Joint Broker) Patrick Claridge / John Howes Instinctif Partners Rozi Morris / Phillip Marriage |
+44 20 3815 8880 +44 (0)20 7457 2020 [email protected] |
Notes to editors
About Feedback plc - www.fbk.com
Feedback plc (AIM: FDBK) is a specialist medical imaging technology company providing innovative software and systems, through its fully-owned trading subsidiary, Feedback Medical Limited. Its products advance the work of radiologists, clinicians and medical researchers by improving workflows and giving unique insights into diseases, particularly cancer.
Feedback has launched Bleepa®, a new secure, encrypted medical communication app for clinicians accessible through smartphones, tablets and desktops that facilitates rapid clinical messaging and review of medical grade imaging for all members of a clinical team, directly from a hospital Picture Archiving and Communications System (PACS). For more information on Bleepa®, see www.bleepa.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
CROEAEFFAAFEEFA